In its active form, GLP-1 (7-36) amide or GLP-1 (7-37) plays a critical role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety
GLP-1 RAs can stabilize blood sugar levels, supporting steady energy throughout the day
This is further complicated by the FDA's increasing concerns about the safety of GLP-1 medications sourced from non-pharmaceutical companies, creating a need for tighter regulation and oversight
The twenty-six week completion rate in Study 1 was 80%
Available at: wada-ama.org
Claims-based data from FairHealth found the number of adults prescribed a GLP-1 drug increased from 0.9% in 2019 to 4% in 2024, and the number of adults with overweight, obesity or diabetes prescribed the medications increased from 0.3% in 2019 to 2.05% in 2024